Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

74.25 -0.31 (-0.42%)
Streaming Delayed Price Updated: 2:38 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
64 65 Next >
AstraZeneca Unusual Options Activity For June 28
Via Benzinga
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
From AstraZeneca
Via Business Wire
Price Over Earnings Overview: AstraZeneca
Via Benzinga
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other... 
Via Benzinga
Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company
Deals, financings, trials and approvals for the week ending June 23. 
Via Talk Markets
This Is What Whales Are Betting On AstraZeneca
Via Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
The European Union has reco 
Via Benzinga
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t 
Via MarketBeat
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News
The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues. 
Via Investor's Business Daily
Is AstraZeneca a Top Stock to Buy Right Now?
The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead. 
Via The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
Via Benzinga
What Does AstraZeneca's Debt Look Like?
Via Benzinga
2 Best Biotech Stocks to Buy Right Now
These international-based pharmaceutical companies pay market-topping dividends to shareholders. 
Via The Motley Fool
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide
The EU's drugs watchdog, the European Medicines Agency, recently raised a thyroid cancer safety signal for Novo Nordisk A/S (NYSE: NVO) drugs, including the much talked semaglutide used i 
Via Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
Why Are Pieris Pharmaceuticals Shares Tanking Today
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4... 
Via Benzinga
Spotify to Launch New Expensive Subscription Plan, Chinese Vendors Bypass US Embargo to Supply Nvidia AI Chips, Eddie Wu To Succeed Daniel Zhang As Alibaba's CEO: Today's Top Stories
Bloomberg 
Via Benzinga
AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions
European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is considered an option amid mounting... 
Via Benzinga
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates... 
Via Talk Markets
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a  
Via Benzinga
AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites
From AstraZeneca
Via Business Wire
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
For the bull run to continue we need broader market participation from SMID caps. 
Via Talk Markets
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e 
Via Benzinga
Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia's AI Technology Stirs Concern: Today's Top Stories
Financial Times 
Via Benzinga
AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder
AstraZeneca Plc (NASDAQ: AZN)  
Via Benzinga
AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes
AstraZeneca plc (NASDAQ: AZN) has entered into a 
Via Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.